• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology >The effect of Metformin on endometrial tumor-regulatory genes and systemic metabolic parameters in polycystic ovarian syndrome -a proof-of-concept study
【24h】

The effect of Metformin on endometrial tumor-regulatory genes and systemic metabolic parameters in polycystic ovarian syndrome -a proof-of-concept study

机译：二甲双胍对多囊卵巢综合征 - 概念研究中的子宫内膜肿瘤调节基因和全身代谢参数的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The aim of this proof-of-concept study was to determine the effects of three-month Metformin therapy on the expression of tumor-regulatory genes [p53, cyclin D2 and BCL-2) in the endometrium of women with polycystic ovary syndrome (PCOS). A total of 40 women, aged between 21 and 45 years with PCOS (Rotterdam criteria) were recruited. The participants were assessed at pre- and 3-month-post-Metformin therapy for the menstrual regularities, weight reduction, Ferriman Galway scores, fasting blood glucose (FBG), total cholesterol, LDL, HDL and p53, BCL-2 and cyclin D2 gene expression. Five participants conceived spontaneously after the initial recruitment. Majority (68%) resumed regular menstrual cycles after Metformin. There were significant reduction in BMI (p=0.001), weight (p=0.001) and Ferriman Galway scores (p=0.001). A significant improvement was seen in mean FBG (p=0.002), total cholesterol (p=0.001), LDL (p=0.003) and HDL cholesterol levels (p=0.015). Tumor suppressor gene (p53) was significantly up-regulated after Metformin (10 out of 14 women), with p value 0.016. BCL-2 and cyclin D2 (oncogenes) were slightly up-regulated without significant difference (p=0.119 and 0.155, respectively). In conclusion, Metformin therapy improved clinical and metabolic parameters in women with PCOS and up-regulated p53 tumor suppressor gene significantly. Further studies are however required to independently validate our findings.
机译：这种概念证明研究的目的是确定三个月二甲双胍治疗对多囊卵巢综合征的妇女子宫内膜中肿瘤调节基因[P53，Cyclin D2和Bcl-2）的影响（PCOS ）。招募了40名女性，招聘了21至45岁的妇女，PCOS（鹿特丹标准）是招募的。在月经正规，减肥，Ferriman Galway评分，空腹血糖（FBG），总胆固醇，LDL，HDL和P53，BCL-2和Cyclin D2，评估参与者的第三个月基因表达。五名参与者在初始招聘后自发地设想。大多数（68％）在二甲双胍后恢复了常规的月经周期。 BMI（P = 0.001），重量（P = 0.001）和Ferriman Galway评分（P = 0.001）显着降低。在平均FBG（P = 0.002）中，总胆固醇（P = 0.001），LDL（P = 0.003）和HDL胆固醇水平（P = 0.015），均显着改善（P = 0.015）。肿瘤抑制基因（P53）在二甲双胍（14名妇女中有10例）后显着上调，P值为0.016。 Bcl-2和细胞周期蛋白D2（癌蛋白酶D2（诱发剂）略微上调而没有显着差异（P = 0.119和0.155分别）。总之，二甲双胍治疗明显改善了妇女患者患者和上调的P53肿瘤抑制基因的临床和代谢参数。但是，需要进一步的研究来独立验证我们的研究结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号